Jim Kastenmayer
General Counsel presso ARRIVENT BIOPHARMA, INC.
Patrimonio netto: 131 914 $ in data 31/03/2024
Profilo
Jim Kastenmayer is currently the Secretary & General Counsel at Arrivent BioPharma, Inc. He previously worked as the Legal Director & Senior Patent Director at AstraZeneca PLC from 2012 to 2019.
He also worked as the Secretary & General Counsel at Spyre Therapeutics, Inc. from 2021 to 2023 and at Viela Bio, Inc. from 2020 to 2021.
Additionally, he worked as an IP Counsel at Medimmune, Inc. Dr. Kastenmayer holds a doctorate degree from Michigan State University, an undergraduate degree from the University of Virginia, and a graduate degree from Georgetown University Law Center.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
ARRIVENT BIOPHARMA, INC.
0.02% | 25/01/2024 | 7 386 ( 0.02% ) | 131 914 $ | 31/03/2024 |
Posizioni attive di Jim Kastenmayer
| Società | Posizione | Inizio |
|---|---|---|
| ARRIVENT BIOPHARMA, INC. | General Counsel | 01/09/2023 |
Precedenti posizioni note di Jim Kastenmayer
| Società | Posizione | Fine |
|---|---|---|
| SPYRE THERAPEUTICS, INC. | Chief Executive Officer | 29/11/2022 |
| VIELA BIO, INC. | General Counsel | 01/03/2021 |
| ASTRAZENECA PLC | General Counsel | 01/12/2019 |
| Medimmune, Inc. | Corporate Officer/Principal | - |
Formazione di Jim Kastenmayer
| Michigan State University | Doctorate Degree |
| University of Virginia | Undergraduate Degree |
| Georgetown University Law Center | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| SPYRE THERAPEUTICS, INC. | Health Technology |
| ARRIVENT BIOPHARMA, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
| Medimmune, Inc. | Health Technology |
Viela Bio, Inc.
 Viela Bio, Inc. BiotechnologyHealth Technology Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD. | Health Technology |
- Borsa valori
- Insiders
- Jim Kastenmayer
